6YG Stock Overview
A commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Immunocore Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$31.00 |
| 52 Week High | US$70.00 |
| 52 Week Low | US$26.40 |
| Beta | 0.72 |
| 11 Month Change | 2.65% |
| 3 Month Change | -3.73% |
| 1 Year Change | -28.90% |
| 33 Year Change | 0% |
| 5 Year Change | n/a |
| Change since IPO | -19.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6YG | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.3% | -0.2% | 0.8% |
| 1Y | -28.9% | -16.9% | 9.1% |
Return vs Industry: 6YG underperformed the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: 6YG underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| 6YG volatility | |
|---|---|
| 6YG Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6YG has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 6YG's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 497 | Bahija Jallal | www.immunocore.com |
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Immunocore Holdings plc Fundamentals Summary
| 6YG fundamental statistics | |
|---|---|
| Market cap | €1.57b |
| Earnings (TTM) | -€44.91m |
| Revenue (TTM) | €282.86m |
5.5x
P/S Ratio-34.9x
P/E RatioIs 6YG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6YG income statement (TTM) | |
|---|---|
| Revenue | US$296.31m |
| Cost of Revenue | US$208.75m |
| Gross Profit | US$87.56m |
| Other Expenses | US$134.61m |
| Earnings | -US$47.05m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.94 |
| Gross Margin | 29.55% |
| Net Profit Margin | -15.88% |
| Debt/Equity Ratio | 116.1% |
How did 6YG perform over the long term?
See historical performance and comparison